Exogenesis Corporation is a privately-held, venture capital backed company developing and commercializing proprietary nanoscale surface modification and surface control technologies which have application in improving the safety and performance of implantable medical devices and improving the performance of optics, glass and a variety of substrates used in the laser, memory and semiconductor industries. Exogenesis NanoAccel technology has the unique ability to produce important atomic level surface modification effects without coatings or additives. The NanoAccel Gas Cluster Ion Beam (GCIB) technology was originally developed to provide nanoscale surface processing of semiconductors and other opto-electronic devices. Exogenesis acquired the exclusive worldwide rights to GCIB intellectual property for biomedical applications. Subsequently, Exogenesis developed a complementary particle beam technology - Accelerated Neutral Atom Beam. Exogenesis welcomes the opportunity to explore interest in commercializing the NanoAccel process. Additional information on NanoAccel technologies and their application can be found at www.exogenesis.us Contact Dmitry Shashkov, Exogenesis President and CEO, at dshashkov@exogenesis.us for more information.